“…It is known to induce cardiovascular adverse events in some cases and is included in pharmacologic agents with possible associations with PAH [ 2 ]. To date, several publications have reported cases of patients who developed PH associated with the use of cyclophosphamide [ [3] , [4] , [5] , [6] , [7] , [8] ]. However, all these cases involved factors other than cyclophosphamide use that might have contributed to the development of PH; some were diagnosed with PH without right heart catheterization (RHC), or with limited clinical and hemodynamic data [ [3] , [4] , [5] , [6] , [7] , [8] ].…”